195 related articles for article (PubMed ID: 11786415)
1. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft.
Kim D; Gregory CW; French FS; Smith GJ; Mohler JL
Am J Pathol; 2002 Jan; 160(1):219-26. PubMed ID: 11786415
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.
Gregory CW; Johnson RT; Presnell SC; Mohler JL; French FS
J Androl; 2001; 22(4):537-48. PubMed ID: 11451350
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft.
Gregory CW; Kim D; Ye P; D'Ercole AJ; Pretlow TG; Mohler JL; French FS
Endocrinology; 1999 May; 140(5):2372-81. PubMed ID: 10218991
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes.
Gregory CW; Hamil KG; Kim D; Hall SH; Pretlow TG; Mohler JL; French FS
Cancer Res; 1998 Dec; 58(24):5718-24. PubMed ID: 9865729
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis levels increase after castration in the CWR22 human prostate cancer xenograft.
Smitherman AB; Gregory CW; Mohler JL
Prostate; 2003 Sep; 57(1):24-31. PubMed ID: 12886520
[TBL] [Abstract][Full Text] [Related]
6. Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma.
Myers RB; Oelschlager D; Manne U; Coan PN; Weiss H; Grizzle WE
Int J Cancer; 1999 Jul; 82(3):424-9. PubMed ID: 10399960
[TBL] [Abstract][Full Text] [Related]
7. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
[TBL] [Abstract][Full Text] [Related]
8. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.
Amler LC; Agus DB; LeDuc C; Sapinoso ML; Fox WD; Kern S; Lee D; Wang V; Leysens M; Higgins B; Martin J; Gerald W; Dracopoli N; Cordon-Cardo C; Scher HI; Hampton GM
Cancer Res; 2000 Nov; 60(21):6134-41. PubMed ID: 11085537
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence.
Huss WJ; Gregory CW; Smith GJ
Prostate; 2004 Jul; 60(2):91-7. PubMed ID: 15162375
[TBL] [Abstract][Full Text] [Related]
10. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.
Gregory CW; Johnson RT; Mohler JL; French FS; Wilson EM
Cancer Res; 2001 Apr; 61(7):2892-8. PubMed ID: 11306464
[TBL] [Abstract][Full Text] [Related]
12. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
13. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.
Nagabhushan M; Miller CM; Pretlow TP; Giaconia JM; Edgehouse NL; Schwartz S; Kung HJ; de Vere White RW; Gumerlock PH; Resnick MI; Amini SB; Pretlow TG
Cancer Res; 1996 Jul; 56(13):3042-6. PubMed ID: 8674060
[TBL] [Abstract][Full Text] [Related]
14. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
[TBL] [Abstract][Full Text] [Related]
15. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer.
Mohler JL; Morris TL; Ford OH; Alvey RF; Sakamoto C; Gregory CW
Prostate; 2002 Jun; 51(4):247-55. PubMed ID: 11987153
[TBL] [Abstract][Full Text] [Related]
16. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Siu SW; Lau KW; Tam PC; Shiu SY
Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
[TBL] [Abstract][Full Text] [Related]
17. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
[TBL] [Abstract][Full Text] [Related]
18. Castration-recurrent prostate cancer is not androgen-independent.
Mohler JL
Adv Exp Med Biol; 2008; 617():223-34. PubMed ID: 18497046
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
20. Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration.
Bladou F; Vessella RL; Buhler KR; Ellis WJ; True LD; Lange PH
Int J Cancer; 1996 Sep; 67(6):785-90. PubMed ID: 8824549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]